Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Migden, MR"'
Publikováno v:
OncoTargets and Therapy, Vol Volume 9, Pp 5671-5678 (2016)
Hung Q Doan,1 Sirunya Silapunt,1 Michael R Migden2,3 1Department of Dermatology, University of Texas, McGovern Medical School, 2Mohs Surgery Unit, Department of Dermatology, 3Department of Head and Neck Surgery, The University of Texas MD Anderson Ca
Autor:
Arron, Sarah, Chang, ALS, Arron, ST, Migden, MR, Solomon, JA, Yoo, S, Day, B-M, McKenna, EF, Sekulic, A
Publikováno v:
Arron, Sarah; Chang, ALS; Arron, ST; Migden, MR; Solomon, JA; Yoo, S; et al.(2016). Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/3qv5w0gc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::58c2ae544b5415f23fc49e49fcd23c35
http://www.escholarship.org/uc/item/3qv5w0gc
http://www.escholarship.org/uc/item/3qv5w0gc
Autor:
Guminski, A, Stull, D, Houghton, K, Gutzmer, R, Migden, MR, Dirix, L, Lewis, KD, Combemale, P, Herd, RM, Kudchadkar, R, Trefzer, U, Sellami, D, Lear, J, Dummer, R
Publikováno v:
In Value in Health May 2016 19(3):A159-A159
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hughes BGM; Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Electronic address: brett.hughes@health.qld.gov.au., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia., Bowyer S; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia., Migden MR; Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Schmults CD; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Khushalani NI; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida., Chang ALS; Department of Dermatology, Stanford University School of Medicine, Redwood City, California., Grob JJ; Aix Marseille University, Hôpital de la Timone, Marseille, France., Lewis KD; University of Colorado Denver Cancer Center, Aurora, Colorado., Ansstas G; Department of Surgical Oncology, Washington University School of Medicine, St Louis, Missouri., Day F; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Ladwa R; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Stein BN; Adelaide Cancer Centre, Adelaide, South Australia, Australia., Muñoz Couselo E; Department of Medical Oncology, Melanoma and Other Skin Tumors Unit, Vall d'Hebron University Hospital, Barcelona, Spain., Meier F; Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Dresden, Germany., Hauschild A; Department of Dermatology, University Hospital (UKSH), Kiel, Germany., Schadendorf D; Department of Dermatology, University Hospital of Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, NCT-West, Campus Essen and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany., Basset-Seguin N; Hôpital Saint-Louis, Paris, France., Modi B; Division of Dermatology, Department of Surgery, City of Hope, Duarte, California., Dalac-Rat S; Hospital Center University Dijon Bourgogne, Dijon, France., Dunn LA; David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, New York., Flatz L; University Hospital Tübingen, Tübingen, Germany., Mortier L; Centre Hospitalier Régional Universitaire de Lille (CHRU), Lille, France., Guégan S; Department of Dermatology, Hôpital Cochin, Paris, France., Heinzerling LM; Department of Dermatology, LMU University Hospital Munich, Munich, Germany; Department of Dermatology, University Hospital Erlangen, Erlangen, Germany., Mehnert JM; Melanoma and Cutaneous Medical Oncology, Perlmutter Cancer Center, NY University, Langone Health, New York, New York., Trabelsi S; CHU de Grenoble - Hôpital A Michallon, Grenoble, France., Soria-Rivas A; Ramón y Cajal University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain., Stratigos AJ; First Department of Dermatology-Venereology, Andreas Sygros Hospital, Athens, Greece; National and Kapodistrian University of Athens Medical School, Athens, Greece., Ulrich C; Charite-Universitatsmedizin Berlin, Berlin, Germany., Wong DJ; UCLA Department of Medicine, Los Angeles, California., Beylot-Barry M; Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France., Bossi P; Department of Biomedical Sciences, Humanitas University, Milan, Italy; IRCCS Humanitas Research Hospital, Milan, Italy., Bugés Sánchez C; Department of Medical Oncology, Skin Tumors Unit, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Barcelona, Spain; Badalona-Applied Research Group in Oncology (B-ARGO), Badalona, Barcelona, Spain., Chandra S; Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Robert C; Gustave Roussy Cancer Center, Villejuif, France., Russell JS; Head and Neck/Cutaneous Medical Oncology, Huntsman Cancer Institute, Salt Lake City, Utah., Silk AW; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Booth J; Regeneron Pharmaceuticals, Inc, Tarrytown, New York., Yoo SY; Regeneron Pharmaceuticals, Inc, Tarrytown, New York., Seebach F; Regeneron Pharmaceuticals, Inc, Tarrytown, New York., Lowy I; Regeneron Pharmaceuticals, Inc, Tarrytown, New York., Fury MG; Regeneron Pharmaceuticals, Inc, Tarrytown, New York., Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Publikováno v:
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Sep 07. Date of Electronic Publication: 2024 Sep 07.
Autor:
Stull CM; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas., Clark D; Department of Dermatology, University of Cincinnati, Cincinnati, Ohio., Parker T; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas., Idriss MH; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas., Patel VA; Department of Dermatology, George Washington School of Medicine and Health Sciences, Washington, District of Columbia., Migden MR; Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: mrmigden@mdanderson.org.
Publikováno v:
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Nov; Vol. 91 (5), pp. 910-921. Date of Electronic Publication: 2024 Jun 26.
Autor:
Idriss MH; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: idriss.munir@marshfieldclinic.org., Stull CM; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Migden MR; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Cancer letters [Cancer Lett] 2024 May 01; Vol. 589, pp. 216821. Date of Electronic Publication: 2024 Mar 21.
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Autor:
Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia danny.rischin@petermac.org., Hughes BGM; Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, Queensland, Australia., Basset-Séguin N; Department of Dermatology, Hôpital Saint-Louis, Paris, France., Schadendorf D; University Hospital Essen and Essen and German Cancer Consortium, Essen, Germany., Bowyer S; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia., Trabelsi Messai S; Department of Dermatology, Grenoble Alpes University Hospital, Grenoble, France., Meier F; Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases Dresden, Dresden, Germany.; Department of Dermatology, University Hospital Carl Gustav Carus, Dresden, Germany., Eigentler TK; Department of Dermatology, Venereology and Allergology, Charité Universitätsmedizin Berlin, Berlin, Germany., Casado Echarren V; Department of Oncology, Oncohealth Institute, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain., Stein B; ICON Cancer Centre, Adelaide, South Australia, Australia., Beylot-Barry M; Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France., Dalac S; Hospital Center University Dijon Bourgogne, Dijon, France., Dréno B; CHU de Nantes and University de Nantes, Nantes, France., Migden MR; Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hauschild A; Schleswig-Holstein University Hospital, Kiel, Germany., Schmults CD; Dermatologic Surgery, Mohs Micrographic Surgery Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lim AM; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Yoo SY; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Paccaly AJ; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Papachristos A; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Nguyen JH; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Okoye E; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Seebach F; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Booth J; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Lowy I; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Fury MG; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Mar 11; Vol. 12 (3). Date of Electronic Publication: 2024 Mar 11.